ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis

Wednesday, January 14, 2015

Submitted by

Mark Ferguson

Source

Source Name: New England Journal of Medicine

Source URL: http://www.nejm.org/doi/full/10.1056/NEJMoa1405760?query=TOC

Author(s)

Harry R. Büller, Claudette Bethune, Sanjay Bhanot, David Gailani, Brett P. Monia, Gary E. Raskob, Annelise Segers, Peter Verhamme, and Jeffrey I. Weitz for the FXI-ASO TKA Investigators

This RCT compared daily 200mg or 300mg of FXI-ASO (an antisense oligonucleotide that reduces levels of factor XI) to daily 40mg of enoxaparin in pts undergoing knee replacement surgery. The end point was thromboembolism. FXI-ASO significantly reduced factor XI levels in a dose-response manner. FXI-ASO 200 mg was equivalent to enoxaparin in frequency of the end point (27% vs 30%) and FXI-ASO was superior (4%). Bleeding was evident in 8% after enoxaparin and in 4% after either dose of FXI-ASO.